Showing results (41-50 of 74) with videos related to
Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2020
Pulmonary Disease Is Associated With Human T-Cell Leukemia Virus Type 1c Infection: A Cross-sectional Survey in Remote Aboriginal CommunitiesLloyd Einsiedel, Hai Pham, Mohammad Radwanur R Talukder, et al.Future Oncology (London, England)|March 24, 2018
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitisCecilia Cs Yeung, David M Hockenbery, Maria Westerhoff, et al.Internal Medicine Journal|March 23, 2022
Activity and outcomes of autologous stem cell transplantation in the private sector in AustraliaKarthik Nath, Yvette James, Debra Taylor, et al.The Oncologist|June 22, 2005
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinomaAndrew X Zhu, Charles S Fuchs, Jeffrey W Clark, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapyKristen J Radford, Cameron J Turtle, Andrew J Kassianos, et al.Journal of Immunological Methods|August 8, 2002
Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: a platform for cancer immunotherapyJ Alejandro López, Georgina Crosbie, Cathryn Kelly, et al.Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.Leukemia & Lymphoma|February 26, 2008
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapseSteven Lane, Russell Saal, Peter Mollee, et al.Pageof 8